Joseph McGill

Phase 1 study of DS‐1205c combined with gefitinib for EGFR mutation‐positive non‐small cell lung cancer

N. Crawford, K. Goto, M. Uno, 2023, Cancer medicine.

Evaluation of combination treatment with DS-1205c, an AXL kinase inhibitor, and osimertinib in metastatic or unresectable EGFR-mutant non-small cell lung cancer: results from a multicenter, open-label phase 1 study

Jie Yang, C. Chiu, T. Hsia, 2023, Investigational New Drugs.